As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry leaders.

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

A company that hardly needs an introduction is Eli Lilly, but what has it been up to lately, and what’s its pipeline strategy? Over the past year, Lilly has mixed headline-grabbing science with ...

Today, Europe stands as a critical region for biotech companies looking to advance medical breakthroughs in specialized fields, including oncology, rare diseases, and cell and gene therapy. In ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...

California-based Cargo Therapeutics has had a rough year with its CAR-T cell therapy firicabtagene autoleucel being discontinued after patients experienced toxic side effects in the clinic. The ...

When Turnstone Biologics was founded, its team had high hopes for the California-based biotech to “lead the fight against solid tumors.” At first, it was keen on developing oncolytic viruses, which ...